AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy
23-Mar-2015 -
AbbVie announced that it has entered into an exclusive worldwide license agreement with C2N Diagnostics to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. This partnership builds upon AbbVie's commitment to ...
Alzheimer's disease
antibodies
tau proteins